The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues

Journal of Biomedical Science

Janja Marc¹  Radko Komadina²  Janja Zupan¹ 

[1] University of Ljubljana, Faculty of Pharmacy, Department of Clinical Biochemistry, Askerceva cesta 7, SI-1000 Ljubljana, Slovenia;General Hospital Celje, Department of Traumatology, Oblakova 5, SI-3000 Celje, Slovenia

关键词: OSCAR;    Cathepsin K;    β₃ integrin;    TGF-β1;    TNF-α;    Interferons;    Interleukins;   

Others  :  825488
DOI  :  10.1186/1423-0127-19-28

 received in 2011-11-02, accepted in 2012-03-01,  发布年份 2012

【 摘 要 】

Background

Pro-inflammatory cytokines possess osteoclastogenic or anti-osteoclastogenic activities. They influence osteoclasts directly or via the receptor activator of nuclear factor κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) system. Recent evidence suggests that inflammation may play a role in osteoporosis (OP) and osteoarthritis (OA). We aimed therefore to determine whether there is a difference between both groups: first, in the expression of the osteoclastogenic and anti-osteoclastogenic cytokines, second, in correlation of these cytokines with bone mineral density (BMD) and levels of bone turnover markers (BTM) and third, in correlation between the expression of these cytokines and osteoclast specific genes and RANK/RANKL/OPG genes.

Methods

Human bone samples from 54 age and sex matched patients with OP or OA were collected during hip arthroplasty surgery. The expression of 25 genes encoding pro-inflammatory cytokines, their receptors, osteoclast specific genes and RANK/RANKL/OPG genes was measured using quantitative real-time PCR. Total hip, femoral neck and lumbar spine BMD and BTM in blood samples were measured. The comparison between OP and OA was assessed using Student's t-test or Mann-Whitney U test and correlations between gene expression, BMD and BTM were determined using nonparametric correlation.

Results

The results demonstrated a higher expression of interleukin (IL)-6 and IL-1α in OP, and interferon (IFN)-γ in OA (p < 0.0005). Negative correlations of total hip BMD with tumor necrosis factor-α (TNF-α) in OA and with RANKL/RANK in OP were found (p < 0.05). Significant correlations with BTM were shown for IL-1α and IFN-γ in OP (rho = 0.608 and -0.634) and for TNF-α, IL-6 and transforming growth factor-β1 (TGF-β1) in OA (rho = 0.591, -0.521 and 0.636). Results showed OP specific negative correlations (IFN-γ with ITGB3, IFN-β1 with CTSK, tartrate resistant acid phosphatase (TRAP), CALCR, RANK, RANKL, IL-1α with CTSK, OPG, IL-17A with CALCR) and positive (TGF-β1 with CTSK, TRAP, RANK), and OA specific negative (IL-1α with osteoclast associated immunoglobulin-like receptor (OSCAR), TNF-α with RANK, RANKL, OPG) and positive (IL-6 with RANK, RANKL, OPG) correlations.

Conclusions

Our results demonstrate that the relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human OP and OA bone and could present an important factor for characteristics of OP and OA bone phenotypes.

【 授权许可】

   
2012 Zupan et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lee SH, Kim TS, Choi Y, Lorenzo J: Osteoimmunology: cytokines and the skeletal system. BMB Rep 2008, 41(7):495-510.
• [2]Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R: IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007, 117(1):122-132.
• [3]Lencel P, Magne D: Inflammaging: The driving force in osteoporosis? Med Hypotheses 2010, 76(3):317-321.
• [4]Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB: The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum 2010, 62(3):647-657.
• [5]Pino AM, Rios S, Astudillo P, Fernandez M, Figueroa P, Seitz G, Rodriguez JP: Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women. J Bone Miner Res 2010, 25(3):492-498.
• [6]Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli LV: Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 1991, 88(12):5134-5138.
• [7]Pfeilschifter J, Koditz R, Pfohl M, Schatz H: Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002, 23(1):90-119.
• [8]Weitzmann MN, Pacifici R: Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006, 116(5):1186-1194.
• [9]Cauley JA, Danielson ME, Boudreau RM, Forrest KY, Zmuda JM, Pahor M, Tylavsky FA, Cummings SR, Harris TB, Newman AB: Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res 2007, 22(7):1088-1095.
• [10]Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J: Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001, 86(5):2032-2042.
• [11]Charatcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL: Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res 2007, 22(5):724-729.
• [12]Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, et al.: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002, 416(6882):744-749.
• [13]Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, et al.: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408(6812):600-605.
• [14]Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP, Sierra O, Pacifici R: Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003, 100(18):10405-10410.
• [15]Janssens K, ten Dijke P, Janssens S, Van Hul W: Transforming growth factor-beta1 to the bone. Endocr Rev 2005, 26(6):743-774.
• [16]Kudo O, Fujikawa Y, Itonaga I, Sabokbar A, Torisu T, Athanasou NA: Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J Pathol 2002, 198(2):220-227.
• [17]Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H: Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000, 275(3):768-775.
• [18]Huang W, Drissi MH, O'Keefe RJ, Schwarz EM: A rapid multiparameter approach to study factors that regulate osteoclastogenesis: demonstration of the combinatorial dominant effects of TNF-alpha and TGF-beta in RANKL-mediated osteoclastogenesis. Calcif Tissue Int 2003, 73(6):584-593.
• [19]Lovibond AC, Haque SJ, Chambers TJ, Fox SW: TGF-beta-induced SOCS3 expression augments TNF-alpha-induced osteoclast formation. Biochem Biophys Res Commun 2003, 309(4):762-767.
• [20]Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL: IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005, 115(2):282-290.
• [21]Lubberts E: IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008, 41(2):84-91.
• [22]Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA: Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003, 32(1):1-7.
• [23]Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S: Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 2008, 283(17):11535-11540.
• [24]Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D: The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15(6):457-475.
• [25]Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ: TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002, 143(3):1108-1118.
• [26]Itonaga I, Sabokbar A, Sun SG, Kudo O, Danks L, Ferguson D, Fujikawa Y, Athanasou NA: Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone 2004, 34(1):57-64.
• [27]Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, et al.: Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191(2):275-286.
• [28]Asagiri M, Takayanagi H: The molecular understanding of osteoclast differentiation. Bone 2007, 40(2):251-264.
• [29]Ralston SH: Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. J Bone Miner Res 1994, 9(6):883-890.
• [30]D'Amelio P, Roato I, D'Amico L, Veneziano L, Suman E, Sassi F, Bisignano G, Ferracini R, Gargiulo G, Castoldi F, et al.: Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporos Int 2010, 22(11):2869-2877.
• [31]Hopwood B, Gronthos S, Kuliwaba JS, Robey PG, Findlay DM, Fazzalari NL: Identification of differentially expressed genes between osteoarthritic and normal trabecular bone from the intertrochanteric region of the proximal femur using cDNA microarray analysis. Bone 2005, 36(4):635-644.
• [32]Kuliwaba JS, Findlay DM, Atkins GJ, Forwood MR, Fazzalari NL: Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. J Bone Miner Res 2000, 15(2):332-341.
• [33]Stewart A, Black AJ: Bone mineral density in osteoarthritis. Curr Opin Rheumatol 2000, 12(5):464-467.
• [34]Harris WH: Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am 1969, 51(4):737-755.
• [35]Logar DB, Komadina R, Prezelj J, Ostanek B, Trost Z, Marc J: Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab 2007, 25(4):219-225.
• [36]Kamolmatyakul S, Chen W, Li YP: Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation. J Dent Res 2001, 80(1):351-355.
• [37]Findlay DM, Atkins GJ: Relationship between serum RANKL and RANKL in bone. Osteoporos Int 2011, 22(10):2597-2602.
• [38]Yan T, Riggs BL, Boyle WJ, Khosla S: Regulation of osteoclastogenesis and RANK expression by TGF-beta1. J Cell Biochem 2001, 83(2):320-325.